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Earlier work from our laboratory provided evidence for myelin abnormalities (decreased quantities of proteins associated with myelin
compaction, decreased sheath thickness) in cortex and hippocampus of Aldh5a1−/− mice, which have a complete ablation of the succinate
semialdehyde dehydrogenase protein [E.A. Donarum, D.A. Stephan, K. Larkin, E.J. Murphy, M. Gupta, H. Senephansiri, R.C. Switzer, P.L. Pearl,
O.C. Snead, C. Jakobs, K.M. Gibson, Expression profiling reveals multiple myelin alterations in murine succinate semialdehyde dehydrogenase
deficiency, J. Inher. Metab. Dis. 29 (2006) 143–156]. In the current report, we have extended these findings via comprehensive analysis of brain
phospholipid fractions, including quantitation of fatty acids in individual phospholipid subclasses and estimation of hexose-ceramide in
Aldh5a1−/− brain. In comparison to wild-type littermates (Aldh5a1+/+), we detected a 20% reduction in the ethanolamine glycerophospholipid
content of Aldh5a1−/−mice, while other brain phospholipids (choline glycerophospholipid, phosphatidylserine and phosphatidylinositol) were
within normal limits. Analysis of individual fatty acids in each of these fractions revealed consistent alterations in n-3 fatty acids, primarily
increased 22:6n-3 levels (docosahexaenoic acid; DHA). In the phosphatidyl serine fraction there were marked increases in the proportions of
polyunsaturated fatty acids with corresponding decreases of monounsaturated fatty acids. Interestingly, the levels of hexose-ceramide (glucosyl- and
galactosylceramide, principal myelin cerebrosides) were decreased in Aldh5a1−/− brain tissue (one-tailed t test, p=0.0449). The current results
suggest that lipid and myelin abnormalities in this animal may contribute to the pathophysiology.
© 2007 Elsevier B.V. All rights reserved.Keywords: Succinate semialdehyde dehydrogenase (SSADH); Aldehyde dehydrogenase 5a1 (Aldh5a1); γ-hydroxybutyric acid; γ-aminobutyric acid (GABA);
Myelin; Phospholipids; Ethanolamine glycerophospholipid; Ethanolamine plasmalogen; Galactosylceramide; Docosohexaenoic acid (DHA)1. Introduction
Heritable succinate semialdehyde dehydrogenase (SSADH;
aldehyde dehydrogenase 5a1 (Aldh5a1) deficiency (OMIM
271980, 610045) is an inborn error of metabolism disrupting the
final step in GABA catabolism [2]. The autosomal-recessively
inherited defect leads to significant increases in GABA and γ-⁎ Corresponding author. Fax: +1 412 692 7816.
E-mail address: michael.gibson@chp.edu (K.M. Gibson).
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.12.008hydroxybutyric acid (GHB) in body fluids derived from affected
patients. Elevated GHB in urine often results in the primary
route of identification (via routine organic acid analysis), and
represents the metabolic basis for the eponym, γ-hydroxybu-
tyric aciduria [3]. Clinically, the phenotype is that of non-
specific mild to severe neurological involvement, including
psychomotor retardation, hypotonia, ataxia, reduced to absent
speech development, and seizures in some patients [4]. Treatment
options are limited, and have been predominantly symptomatic,
such as carbamazepine for seizures, haloperidol for psychiatric
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most widely employed pharmacotherapy is Sabril® (vigabatrin;
γ-vinyl GABA), an inhibitor of the enzymatic reaction preceding
SSADH, GABA transaminase. The rationale for vigabatrin in-
tervention derives from its capacity to decrease the production of
GHB (Fig. 1) [6]. Nonetheless, since vigabatrin also elevates
cerebral GABA [6], its utility in SSADH deficiency may require
re-evaluation since this is already a hyperGABAergic syndrome.
The absence of effective therapies, coupled to inadequate
insights into underlying pathophysiology, led Hogema and
colleagues [7] to develop a knockout model for this disorder
(Aldh5a1−/− mice). These animals are born at the expected
Mendelian frequencies (∼25%), fail to gain measurable weight,
transition from absence seizures at ∼2 weeks of life to
generalized tonic–clonic convulsion at 3–4 weeks of life and
eventual lethal status-epilepticus thereafter [8–10]. A variety of
metabolic disturbances have been detected in Aldh5a1−/− mice
in both physiological fluids and tissue extracts. These include
significant changes in GABA, GHB, homocarnosine (the
GABA-histidine dipeptide), succinate semialdehyde, 4,5-dihy-
droxyhexanoate, D-2-hydroxyglutarate, guanidinoacetate, gua-
nidinobutyrate, glutamine, neuroactive steroids, monamines
and others [11–17]. Alterations in GABAB- and GABAA-
receptors levels and isoforms, in the presence of unchanged
glutamatergic transmission, suggest that imbalanced inhibitory/
excitatory neurotransmission may underlie the mechanism of
seizure transition [9,10]. Early lethality in Aldh5a1−/− mice
afforded the opportunity to examine new treatment modalities,
with preliminary studies revealing that antagonists of both the
GHB- and GABAB-receptors, as well as application of the non-
physiological amino acid taurine, led to significant lifespan
extension for these mice [11].
Earlier studies from our laboratory utilized microarray gene
expression studies in an attempt to identify novel pharma-
cotherapeutic targets for Aldh5a1−/− mice [1]. Unexpectedly,
those investigations led to the discovery of significant altera-
tions in myelin-associated genes in the hippocampus and cortexFig. 1. Interactions of the Krebs cycle and GABA shunt in central nervous
system. The site of the block in patients with SSADH deficiency (and
Aldh5a1−/− mice) is depicted by the italicized enzyme name Aldh5a1.
Abbreviations employed: α-KG, α-ketoglutarate; glu, glutamate; GHB,
γ-hydroxybutyrate; GABA, γ-aminobutyrate; SSA, succinate semialdehyde.
Increased intermediates detected in Aldh5a1−/− mice and SSADH-deficient
patients are shown with upward-oriented arrows.of these animals. To further dissect these myelin abnormalities,
we have performed a comprehensive examination of brain
phospholipid mass and composition in Aldh5a1−/− and
Aldh5a1+/+ mice, accompanied by analysis of individual
phospholipid fatty acid composition. Hexose-ceramides, (e.g.,
glucosyl- and galactosyleceramides, markers of myelin integ-
rity) were also quantified in the same tissues. Our data suggest
that fatty acid anomalies in glycerophospholipid fractions may
play a pathophysiological role in this disorder.
2. Methods
2.1. Animals
Age- and sex-matched wild-type (Aldh5a1+/+) and gene-ablated mice
(Aldh5a1−/−) on the C57Bl background (age 17–19 days) were used in all
experiments. Both groups of animals were maintained on normal mouse chow.
Aldh5a1+/+ and Aldh5a1−/− mice were derived by heterozygote littermate
intercrosses. Animals were euthanized by carbon dioxide inhalation and cervical
dislocation according to the guidelines “Public Health Service Policy onHumane
Care and Use of Laboratory Animals” approved by the IACUC of Oregon Health
and Science University (protocol #A-773). Whole intact brains were rapidly
excised from the skull and point frozen in dry-ice/liquid nitrogen with long-term
storage at −80 °C. Brain lipids were extracted quantitatively from pulverized
frozen whole brain with hexane-2-propanol (3:2, vol/vol) [21]. For the majority
of studies, 5–7 animals each were utilized for analyses, with the exception of
hexose-ceramide studies which employed n=4 animals for each genotype.
2.2. Thin layer chromatography
Individual phospholipid classes and neutral lipids were separated by thin
layer chromatography.Whatman silica gel −60 plates (20×20 cm, 250 μm)were
heat-activated at 110 °C for 1 h and samples streaked onto plates. Phospholipids
were separated using chloroform:methanol:acetic acid:water (55:37. 5:3:2) by
volume [18]. Lipid fractions were identified using authentic standards (Doosan-
Serday, Englewood Cliffs, NJ and NuChek Prep, Elysian, MN). Phospholipid
mass was determined by assaying for lipid phosphorus content of individual
separated lipid classes [19]. Neutral lipids were separated in petroleum ether:
diethyl ether:acetic acid (75:25:1.3 by vol) [20]. Cholesterol was assayed using
an iron binding assay after separation by TLC as described previously [21].
2.3. Fatty acid analysis
The ethanolamine glycerophospholipids (EtnGpl), choline glyceropho-
spholipids (ChoGpl), phosphatidylinositol (PtdIns) and phosphatidylserine
(PtdSer) fractions were separated by high performance liquid chromatography
[22]. Each fraction was subjected to base-catalyzed transesterification,
converting the phospholipid acyl chains to fatty acid methyl esters (FAME).
To each fraction, 2 mL of 0.5 M KOH dissolved in anhydrous methanol were
added [23]. FAME were extracted from the methanol using 2 mL of n-hexane
and the n-hexane phase containing the FAME was removed. The lower phase
was re-extracted two more times with 3 mL of n-hexane and these washes were
combined with the original aliquot.
Individual fatty acids were separated by gas liquid chromatography (GLC)
and quantified using flame ionization detection using an SP-2330 column
(0.32 mm ID×30 m length) and a Trace GLC (ThermoElectron, Austin, TX)
equipped with dual autosamplers and dual flame ionization detectors (FID). For
each fatty acid, peak areas were converted to moles using a standard curve from
commercially purchased standards (NuChek Prep, Elysian, MN) and 17:0 as the
internal standard.
2.4. Hexose-ceramide determinations
Tandem mass spectrometry, using multiple reaction monitoring with isotope
dilution, was employed for determination of glycosphingolipids, which included
Table 2
Fatty acid composition of brain ethanolamine glycerophospholipids from
Aldh5a1+/+ and Aldh5a1−/− mice
EtnGpl
mol% Aldh5a1+/+ Aldh5a1−/−
FAME Mean SD Mean SD
16:0 8.6 0.9 8.5 1.1
18:0 26.1 0.8 27.4 0.3*
18:1 n-9 8.4 1.2 7.6 0.4
18:1 n-7 1.7 0.2 1.5 0.0
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hexose-ceramide (glucosyl- and galactosylceramide are not differentiated) and
sphingomyelin were quantified, and the ratio (hexose-ceramide/sphingomyelin)
determined to correct for individual variation. Complete methodological details
have been previously reported [24–26].
2.5. Statistics
Statistical analysis was performed using Instat 2 from GraphPad (San Diego,
CA). Statistical significance was assessed using two-way, unpaired Student's t-
test, with p<0.05 considered significant.18:2 n-6 0.7 0.1 0.8 0.2
20:1 n-9 0.8 0.3 0.5 0.05*
20:3 n-6 0.7 0.2 0.6 0.1
20:4 n-6 23.4 0.6 22.9 0.4
22:4 n-6 5.9 0.3 5.3 0.2*
22:6 n-3 23.7 1.0 25.0 1.0
sat 34.8 1.3 35.9 1.4
unsat 65.2 1.3 64.1 1.4
MUFA 10.9 1.6 9.6 0.4
PUFA 54.4 1.0 54.6 1.3
n-3 23.7 1.0 25.0 1.0
n-6 30.7 0.6 29.6 0.5
n-3/n6 0.77 0.04 0.84 0.03*
unsat/sat 1.88 0.10 1.79 0.11
PUFA/MUFA 5.13 0.90 5.71 0.28
MUFA/sat 0.31 0.06 0.27 0.02
PUFA/sat 1.57 0.06 1.52 0.09
Values are expressed as mole percentage and represent mean±SD, n=5–7. The
* indicates a significant difference between groups, p<0.05. Abbreviations
employed for Tables 2–6: FAME, fatty acid methyl esters; n-3, n-6, n-7, n-9, etc-
refers to omega-3, omega-6, etc; sat, saturated; unsat, unsaturated; MUFA,
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; chol,
cholesterol; PL, phospholipids.3. Results
3.1. Brain phospholipid mass and composition
The total phospholipid mass was not altered in Aldh5a1−/−
mice; however, EtnGpl mass was decreased 20% in these
animals (Table 1). This result is consistent with the 30%
decrease in ethanolamine plasmalogen mass previously
reported [1]. Thus, Aldh5a1gene ablation in the mouse affected
only EtnGpl, and more specifically the ethanolamine plasmalo-
gen subclass.
3.2. Brain individual phospholipid fatty acid composition
The fatty acid composition of the four main brain
phospholipids, EtnGpl, choline glycerophospholipid (ChoGpl),
phosphatidylserine (PtdSer) and phosphatidylinositol (PtdIns),
was analyzed (Tables 2–5). In EtnGpl, the proportion of 18:0
was increased 1.05-fold, while proportions of 20:1n-9 and
22:4n-6 were decreased 37% and 10%, respectively. Although
the total n-3 and n-6 fatty acid contents were not statistically
different, the n-3 to n-6 ratio was increased 1.1-fold. In
ChoGpl, proportions of 22:6n-3 were increased 1.2-fold in
Aldh5a1−/− mice, accounting for a significant increase in the n-
3 to n-6. In PtdIns, the proportion of 20:4n-6 was decreasedTable 1
Brain phospholipid mass in Aldh5a1+/+ and Aldh5a1−/− mice
Aldh5a1+/+ Aldh5a1−/− Aldh5a1+/+ Aldh5a1−/−
nmol/g ww mol%
Mean SD Mean SD Mean SD Mean SD
Ptd2Gro 1051 142 922 332 2.3 0.3 2.0 0.5
PtdGro 959 175 899 260 2.1 0.5 2.0 0.5
PtdOH 464 128 554 249 0.9 0.2 1.2 0.4
EtnGpl 11852 1025 9539 1587* 24.1 1.5 21.6 2.1*
PtdIns 2228 217 1952 402 4.7 0.5 4.4 0.4
PtdSer 4207 852 4134 1155 8.6 1.5 9.2 1.1
ChoGpl 23126 2004 21883 3447 48.3 2.0 49.5 2.3
CerPCho 4357 863 4482 1126 9.0 1.9 10.0 1.0
Total 48244 3559 44366 7986
Values are expressed as mole percentage and represent mean±SD, n=5–7.
Abbreviations: Ptd2Gro: cardiolipin; PtdGro: phosphatidylglycerol; PtdOH:
phosphatidic acid; EtnGpl: ethanolamine glycerophospholipids; PtdIns: phos-
phatidylinositol; PtdSer: phosphatidylserine; ChoGpl: choline glyceropho-
spholipid; CerPCho: sphingomyelin. The * indicates a significant difference
between groups, p<0.05.15% affecting the n-3 to n-6 ratio which was increased 1.7-fold,
indicating a net increase in n-3 fatty acids relative to n-6. In
PtdSer, proportions of 18:1n-9 and 20:1n-9 decreased 20% and
37% respectively, while the proportion of 22:6n-3 was
increased 1.1-fold. The increase in n-3 fatty acids was
accompanied by decreased n-6 fatty acids, thereby affecting
the n-3 to n-6 ratio.
3.3. Brain neutral lipid mass
Because brain is highly enriched in cholesterol, the effects of
Aldh5a1 deletion on brain cholesterol mass were determined
(Table 6). Aldh5a1−/− mice did not have a significant change in
brain cholesterol mass as compared to wild-type. Because
neither the brain total phospholipid content nor the brain
cholesterol content was changed, there was no change in the
cholesterol to phospholipid ratio.
3.4. Brain glycosphingolipids
Glucosyl- and galactosylceramides (e.g., hexose-ceramides)
are major components of myelin in both grey and white matter.
Accordingly, these were quantified in extracts of brains derived
from Aldh5a1−/− and Aldh5a1+/+ mice (Fig. 2). The ratio of
hexose-ceramide to sphingomyelin was employed to correct for
Table 3




FAME Mean SD Mean SD
16:0 51.2 1.3 51.5 0.7
16:1 0.9 0.1 0.9 0.1
18:0 10.7 0.5 10.6 0.3
18:1 n-9 17.1 0.2 16.7 0.1*
18:1 n-7 5.1 0.2 5.0 0.1
18:2 n-6 1.3 0.5 1.2 0.1
20:1 n-9 0.6 0.1 0.6 0.1
20:3 n-6 0.4 0.0 0.5 0.1*
20:4 n-6 9.0 0.6 8.5 0.3
22:4 n-6 0.6 0.1 0.7 0.1
22:6 n-3 3.3 0.4 3.9 0.3*
sat 61.9 1.0 62.1 0.6
unsat 38.1 1.0 37.9 0.6
MUFA 23.6 0.3 23.2 0.1
PUFA 14.4 1.0 14.6 0.4
n-3 3.3 0.4 3.9 0.3*
n-6 11.1 0.9 10.8 0.2
n-3/n6 0.30 0.05 0.36 0.03*
unsat/sat 0.62 0.03 0.61 0.01
PUFA/MUFA 0.61 0.05 0.63 0.02
MUFA/sat 0.38 0.01 0.37 0.01
PUFA/sat 0.23 0.02 0.24 0.01
Values are expressed as mole percentage and represent mean±SD, n=5–7. The
* indicates a significant difference between groups, p<0.05.
Table 5




FAME Mean SD Mean SD
16:0 3.8 0.3 3.7 0.4
18:0 42.1 0.6 41.9 0.9
18:1 n-9 10.1 1.3 8.0 0.5*
18:1 n-7 1.3 0.1 1.1 0.0
18:2 n-6 0.5 0.1 0.4 0.1
20:1 n-9 0.8 0.2 0.5 0.04*
20:3 n-6 0.8 0.3 0.7 0.2
20:4 n-6 5.8 0.4 5.3 0.3
22:4 n-6 4.7 0.3 4.8 0.3
22:6 n-3 30.1 1.2 32.9 0.8*
sat 46.0 0.6 45.6 1.0
unsat 54.0 0.6 54.4 1.0
MUFA 12.2 1.6 9.6 0.5*
PUFA 41.8 1.4 44.8 0.7*
n-3 30.1 1.2 32.9 0.8*
n-6 11.7 0.6 11.8 1.3
n-3/n6 2.59 0.16 2.82 0.34
unsat/sat 1.18 0.03 1.19 0.05
PUFA/MUFA 3.49 0.64 4.65 0.22*
MUFA/sat 0.27 0.04 0.21 0.01*
PUFA/sat 0.91 0.03 0.98 0.04*
Values are expressed as mole percentage and represent mean±SD, n=5–7. The
* indicates a significant difference between groups, p<0.05.
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genotype: Aldh5a1+/+, 17.9±4.2; Aldh5a1−/−, 10.5±6.0;
unpaired one-tailed t-test, p=0.0449). Although we predicted
a decrease, ganglioside analysis in the same brain fractions didTable 4




FAME Mean SD Mean SD
16:0 12.2 1.7 13.9 2.8
18:0 37.5 1.4 37.9 4.1
18:1 n-9 6.2 0.5 6.0 0.2
18:1 n-7 2.9 0.5 2.5 0.4
20:4 n-6 34.9 2.2 29.5 4.0*
22:4 n-6 1.9 0.6 2.1 0.7
22:6 n-3 3.4 0.8 4.2 0.5
sat 49.7 1.5 51.9 4.7
unsat 50.3 1.5 48.1 4.7
MUFA 10.2 2.5 8.6 0.6
PUFA 40.2 3.1 37.9 5.2
n-3 3.4 0.8 4.8 1.2
n-6 36.8 2.7 31.7 4.2*
n-3/n6 0.09 0.02 0.15 0.04*
unsat/sat 1.01 0.06 0.94 0.16
PUFA/MUFA 4.15 0.96 4.58 0.64
MUFA/sat 0.20 0.05 0.20 0.08
PUFA/sat 0.81 0.08 0.74 0.15
Values are expressed as mole percentage and represent mean±SD, n=5–7. The
* indicates a significant difference between groups, p<0.05.not reveal significant alterations between genotypes (data not
shown).
4. Discussion
In the current study, we observed a significant decrease in
ethanolamine glycerophospholipid mass that was consistent
with the 30% decrease in ethanolamine plasmalogen reported
by Donarum and coworkers [1]. The data of Table 1 indicate
that the loss of Aldh5a1 activity in the mouse affected only the
ethanolamine glycerophospholipid fraction of brain, and more
specifically the ethanolamine plasmalogen subclass. Ethanola-
mine plasmalogen is a major constituent of myelin, and certain
species of this plasmalogen are unique to the myelin sheath
[27]. Isolated decreases in ethanolamine plasmalogen fractions
have been detected in other mouse models and human disorders.
Ethanolamine plasmalogen was significantly decreased in brain
and spinal cord derived from the Quaking mouse, as well as
brain derived from the Jimpy mouse [27]. The Quaking mouseTable 6
Total brain cholesterol and phospholipid mass in Aldh5a1+/+ and Aldh5a1−/−
mice
Fraction Aldh5a1+/+ Aldh5a1+/+ Aldh5a1−/− Aldh5a1−/−
Mean SD Mean SD
Chol 23870 4024 20495 2844
Total PL 48244 3559 44366 7986
Chol/PL ratio 0.50 0.10 0.47 0.06
Values are expressed as mass (nmol/g ww) and represent mean±SD, n=5–7.
The * indicates a significant difference between groups, p<0.05.
Fig. 2. Ratio of hexose-ceramide (including glucosyl- and galactosylceramide)
to sphingomyelin in brain tissue derived from wild-type (Aldh5a1+/+) and
mutant (Aldh5a1−/−) mice as determined by electrospray tandem mass
spectrometry. For each genotype, n=4 animals. See Methods for details of
quantitation.
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phenotype, characterized as severe tremor of voluntary move-
ments with onset at ∼ day of life 10. In this animal, an 1 Mb
deletion in the qk gene leads to significant oligodendrocyte
alterations and CNS dysmyelination [28]. The Jimpy mouse
harbors an X-linked mutation in proteolipid protein (PLP)
which results in severe CNS dysmyelination affecting glial and
neural populations [29]. PLP is a key protein required for
maintenance of the multilamellar myelin sheath structure and
axonal integrity [1], and its decreased expression in Aldh5a1−/−
brain was demonstrated by both microarray and quantitative
RTPCR [1]; Western blotting of PLP is in progress to support
these initial findings. These observations suggest that myelin
abnormalities occurring in the Aldh5a1−/− brain may best be
characterized as dysmyelination, although to date there has been
no convincing evidence for dysmyelination in patients with
SSADH (Aldh5a1) deficiency.
Abnormalities of ethanolamine glycerophospholipids have
been observed in human neurological disorders and induced-
states in rodents. Decreased ethanolamine glycerophosphatides
are detected in gray matter and frontal lobe myelin obtained
post-mortem from a 57-year-old patient with Refsum's disease
[30]. In white matter myelin derived from 13/17 patients with
multiple sclerosis (MS), the ratio of different molecular
species of enthanolamine plasmalogen was comparable to
control values but was significantly altered in the remaining
4 MS cases and in samples derived from a patient with
subacute sclerosing panencephalitis [31]. Sun and coworkers
[32] demonstrated adaptive increases in ethanolamine plasma-
logen synthesis in synaptosomes derived from rats treated
chronically with ethanol. Conversely, Bichenkov and Ellingson
[33] demonstrated that ethanolamine plasmalogen synthesis in
the CG-4 oligodendrocyte cell line could be both up- and down-
regulated dependent upon the developmental time period of
acute ethanol exposure. Since ethanol and GHB have many
similar pharmacological properties (and synergistic capabilities)[34], it is interesting to speculate that the ethanolamine
plasmalogen abnormalities detected in Aldh5a1−/− mice corre-
late with chronic GHB exposure in the CNS, which is a
testable hypothesis in rodent model systems treated chroni-
cally with GHB.
Galactosylceramide (hexose-ceramide; galactosecerebro-
side) represents the major sphingolipid of the myelin membrane
[35,36]. In the current study, galactosylceramide was notably
lower in Aldh5a1−/− mice in comparison to wild-type
littermates. Quantitation of galactosylceramide is generally
considered a sensitive marker for myelin destruction [37]. The
ratio of hexose-ceramide to sphingomyelin represents a reliable
indicator of whether the hexose-ceramide is actually lower in a
particular study group. In our investigation, sphingomyelin was
employed as an indicator of overall cellular glycolipid content
in lieu of going through more sophisticated assays for absolute
galactosylceramide quantitation. It is important to note that
sphingomyelin mass was not altered in these mice (Table 1).
Vanier [38] noted a severe loss of galactosylceramide in
Niemann–Pick type C patients exhibiting the severe or late-
infantile forms of the disease. Similarly, Hara and Taketomi [39]
analyzed cerebral lipids in an infant male with Menkes' disease,
noting a significant decrease in galactosylceramide in myelin
sheath associated with defective copper metabolism. Mice
unable to produce galactosylceramide exhibit thin, unstable
myelin which often leads to progressive demyelination and
significant motor coordination defects [35,40,41]. For example,
in the twitcher mouse (a model of globoid cell leukodystrophy)
there is a reduction of C24:1 and C24:1 hydroxylated
galactosylceramide species, associated with the acute demye-
lination in this animal model [40]. We hypothesize that the
reduced galactosylceramide detected in our studies (Fig. 2)
correlates with the reduced myelin sheath thickness quantified
in cortical sections of Aldh5a1−/− mice [1].
To extend our findings of decreased ethanolamine
glycerophospholipid level in the brain of Aldh5a1−/− mice,
we subjected each of the individual phospholipid fractions to
exhaustive fatty acid analyses (Tables 2–5). There were
significant differences for Aldh5a1−/− mice in comparison to
wild-type littermates for a variety of fatty acids; however, the
most consistent results were increased n-3 (omega-3) fatty
acids, principally 22:6 n-3 (docosahexaenoic acid; DHA). We
predict that the alterations detected in omega-3 fatty acids and
plasmalogens in the Aldh5a1−/− mice can be tracked to the
endoplasmic reticulum and specific alterations in selected
desaturase enzymes, a hypothesis that is currently under
investigation in the laboratory. The phosphatidylserine fraction
derived from Aldh5a1−/− mice showed a significant decrease
in monounsaturated fatty acids coupled with a corresponding
increased in polyunsaturated fatty acids (Table 5). The
resultant ratios of unsaturated to saturated fatty acids were
also altered. Similar alterations in unsaturated fatty acids have
been detected in cerebral myelin and synaptosomes from
phenylketonuric brain and hyperphenylalaninemic chick
embryos [42,43], as well as in cerebral lipids derived from
an infantile case of Menkes' disease [39]; however, it is likely
that the mechanisms leading to unsaturated fatty acid
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the Aldh5a1 animal model.
Correlation of clinical and biochemical features between
Aldh5a1 deficient patients and knockout mice remains
challenging. Both patients and mice manifest a neurological
phenotype (ataxia in mice and patients, hypotonia and
retardation in patients), but a vexing issue is the occurrence
of seizures, which is uniform in the mouse model yet only
∼50% prevalent in human patients. Neuroimaging in patients
indicates signal abnormalities in deep grey matter structures
(basal ganglia), yet myelin anomalies would indicate white
matter alterations. With regard to plasmalogen abnormalities
in Aldh5a1−/− mice, it is of interest that the white matter pool
of plasmalogens turns over much more slowly than pools
associated with grey matter, suggesting that grey matter pools
have a signaling role. The processes at play in Aldh5a1
deficiency, however, may have quite different etiologies while
simultaneously contributing to the phenotype. For example,
increased signal intensity in the basal ganglia may derive from
chronic oxidative damage, and recent data has shown that
GHB ellicits oxidant stress [44]. GABA is key to the distri-
bution of myelin sheaths in early development [1], and almost
certainly plays a role (with GHB) in alterations of inhibitory
neurotransmission that have been detected in Aldh5a1−/− mice
that underlie the genesis of seizures [9,10]. Accordingly, the
alterations we have seen in myelin (and likely fatty acid
profiles) are almost certainly a secondary phenomenon related
to primary accumulation of GHB and GABA in brain.
One limitation in the current investigation is that our
analyses were focused on a single developmental time point
(17–19 days of life), a period of rapid myelination in certain
regions of the CNS [1]. Further studies assessing myelin and
lipid structures in younger Aldh5a1−/− mice, as well as those
who have survived the early-onset seizure activity associated
with this disorder, are planned. These studies are currently in
progress.
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